From February 17, 2024 to March 31, 2024, the company has repurchased 3,469,900 shares, representing 0.74% for CLP 57.33 million. With this, the company has completed the repurchase of 3,469,900 shares, representing 0.74% for CLP 57.33 million under the buyback announced on February 19, 2024.
Vcanbio Cell & Gene Engineering Corp., Ltd
Equities
600645
CNE000000545
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.93 CNY | +1.46% |
|
-2.33% | -21.41% |
1st Jan change | Capi. | |
---|---|---|
-21.41% | 997M | |
-9.24% | 11.78B | |
-23.11% | 6.59B | |
+6.07% | 5.66B | |
+24.14% | 5.46B | |
-24.21% | 3.45B | |
+4.96% | 2.5B | |
+32.86% | 2.29B | |
-67.96% | 2.21B | |
-13.25% | 2.2B |
- Stock Market
- Equities
- 600645 Stock
- News Vcanbio Cell & Gene Engineering Corp., Ltd
- Tranche Update on Vcanbio Cell & Gene Engineering Corp., Ltd's Equity Buyback Plan announced on February 19, 2024.